Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

SELECT Cardiovascular Trial Information | Novo Nordisk Medical

Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6 | Semantic Scholar

Semaglutide reduces cardiovascular events in adults who are overweight by 20%, study finds - The Pharmaceutical Journal

Wegovy confers reductions in cardiovascular risk, regardless of weight loss

The weight-loss drug Wegovy lowered heart attack risk in a large trial

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | New England Journal of Medicine

Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity | JACC

In people with diabetes or obesity and cardiovascular risk, semaglutide boosts regenerative cells and reduces inflammation, supporting natural vessel repair. Read more about the SEMA-VR trial in #EHJ. https://t.co/czH6rAUS9e #cardiotwitter #ESCcongress ...

Semaglutide and Cardiovascular Outcomes in Obesity | NEJM

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials | Cardiovascular Diabetology | Springer Nature Link

Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial | CNN

New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss - American College of Cardiology